Your Health, We Care
Belzutifan is indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
FDA，2021.08
Applicable to von Hippel-Lindau (VHL) disease patients requiring treatment for r···【more】
Release date：2026-01-05Recommended：13
Lucius Version of Belzutifan: Dosage and Administration, Indications, Precaution···【more】
Release date：2025-12-04Recommended：60
